top of page
Tissue visualization

A Fusion of Vision, Innovation, and Expertise

From Academic Collaboration to Oncology Innovation: The Founding of IMAI

Tissue visualization



The beginning of IMAI can be traced back to Francesca Catto's collaboration during her Ph.D. at the Aguzzi Laboratory with Stephan Fox, a product development and mechanical engineering specialist at ETH. Their innovative efforts were later strengthened by Robert Axelrod during his PhD at the Mathys lab, and by Sascha Brun, who joined the project during his master's studies under Fox's guidance. Officially founded in 2024 by Robert, Francesca, and Sascha, IMAI welcomed Martina and Beda to the team, furthering its mission to revolutionize cancer diagnostics through the application of 3D histology.  



IMAI is on a mission to redefine the landscape of oncology diagnostics through its pioneering 3D histology technology. By focusing on the early and accurate diagnosis of cancer, IMAI aims to enhance therapeutic outcomes and significantly improve patient care.



Envisioning a future in which its cutting-edge histology technology becomes a cornerstone of clinical practice, IMAI is committed to transforming the approach to cancer diagnosis. This vision includes early stage diagnosis and a deeper understanding of cancer mechanisms, which will lead to optimized treatment plans and better outcomes for patients worldwide.

Meet the Visionaries Behind IMAI

United by a shared passion for transforming patient care and a commitment to excellence, our team combines diverse expertise in biomedicine, engineering, software development, and research. Each member brings a unique set of skills and experiences, driving IMAI towards new frontiers in medical technology.

Meet the Advisors

Behind IMAI is a distinguished panel of advisors, each a luminary in their respective fields. From the intricacies of neuropathology to the frontiers of engineering and the depths of food, nutrition, and health sciences, our advisors bring a wealth of knowledge, experience, and strategic insight.
Prof. Dr. med. Adriano Aguzzi

Head of Scientific advisory board. Director of Neuropathology at University hospital Zurich

Dr. med. Daniel Kirschenbaum

MD PhD Consultant neuropathologist, University Hospital Zurich

Dr. Stephan Fox

Lead Engineering at Feasibility LAB, ETH Zürich

Prof. Dr. Mirko Meboldt

Head of Faculty Conference / Head of CAS ETH Applied Manufacturing Technology. / Deputy Head of Institute for Machine Tools and Manufacturing. ETH Zürich

Prof. Dr. Alexander Mathys

Associate Professor at the Department of Health Sciences and Technology


Elevate Accuracy, Embrace Innovation:

Transform Tissue Analysis into an Automated, 3D Histology Experience

bottom of page